3D-Printed GelMA Microneedles with Multilayer Therapeutic Properties for Diabetic Wound-Relevant Drug Delivery
- 1Yildiz Technical University , , ,
- 2Marmara University , , ,
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by impaired insulin secretion, reduced insulin sensitivity, and hyperglycemia. Diabetic wounds are among the major complications of T2DM and can lead to chronic wounds due to challenges in the normal healing process. In this study, a three-layered tissue scaffold incorporating microneedles (MNs) was developed for diabetic wound management. The scaffold was fabricated using digital light processing (DLP) for the GelMA-based layers and electrohydrodynamic atomization (EHDA) for the surface coating, combining antibacterial, metabolic, and antioxidant functions within a single platform. The first two layers were designed using gelatin methacrylate (GelMA) and produced via DLP. The first layer was loaded with the antibiotic amoxicillin to prevent infection at the scaffold application site. In the second layer, MNs containing metformin were designed. For the outermost layer, polylactic acid (PLA) microparticles containing antioxidant and antibacterial salicylic acid (SA) were produced via the EHDA method and coated onto the scaffold surface. This three-layered scaffold was characterized by SEM, FT-IR, DSC, and mechanical, swelling, degradation, and penetration analyses. In vitro studies of single-drug-loaded model formulations demonstrated biphasic drug-release behavior over 72 h, effective antibacterial activity against E. coli and S. aureus, and favorable cytocompatibility. Oxidative-stress assays showed lower Total Oxidant Status (TOS) levels and higher Total Antioxidant Status (TAS) values in the drug-loaded formulations, while the scratch assay demonstrated increased wound-gap closure under hyperglycemic culture conditions. Overall, the multilayer microneedle platform exhibited antibacterial activity, with inhibition zones of up to 23 mm, and favorable cytocompatibility, with cell viability remaining above 77% across all formulations. These findings provide in vitro proof-of-concept evidence for the multifunctional design of the platform but do not demonstrate wound-healing efficacy in diabetic tissue.
Related
- Microneedles for Chronic Refractory Wounds: A Review of Dynamic Regulation Strategies and Therapeutic Applications.
- Adaptive Intelligent Microneedles for Sustained Wound Healing: Translating Microenvironment Signals into Stage-Specific Therapeutic Responses
- Editorial: Frontiers in diagnostic and therapeutic approaches in diabetic sensorimotor neuropathy, volume II
- Diabetic retinal neurovascular unit injury: mechanisms, imaging evaluation, and integrated therapeutic strategies
- Expanding Therapeutic Target Space from Genes to Disease-Relevant Molecular Forms with Agent3Diso
BibTeX
@article{saraj20263dprinted,
title = {{3D-Printed GelMA Microneedles with Multilayer Therapeutic Properties for Diabetic Wound-Relevant Drug Delivery}},
author = {Shhd Saraj and Kaan Danis and Selcen Ari Yuka and Pelin Pelit Arayici and Sule Ilgar and Meryem Akkurt Yıldırım and Elif Kaya and Elif Ilhan and Gulgun Tınaz and Azime Erarslan and Oguzhan Gunduz and Cem Bulent Ustundag},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c06574},
url = {https://pubs.acs.org/acsodf/article/11/42/64986/5452050/3D-Printed-GelMA-Microneedles-with-Multilayer},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - 3D-Printed GelMA Microneedles with Multilayer Therapeutic Properties for Diabetic Wound-Relevant Drug Delivery
AU - Shhd Saraj
AU - Kaan Danis
AU - Selcen Ari Yuka
AU - Pelin Pelit Arayici
AU - Sule Ilgar
AU - Meryem Akkurt Yıldırım
AU - Elif Kaya
AU - Elif Ilhan
AU - Gulgun Tınaz
AU - Azime Erarslan
AU - Oguzhan Gunduz
AU - Cem Bulent Ustundag
PY - 2026
DA - 2026/10/15
JO - ACS Omega
DO - 10.1021/acsomega.6c06574
UR - https://pubs.acs.org/acsodf/article/11/42/64986/5452050/3D-Printed-GelMA-Microneedles-with-Multilayer
AB - Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by impaired insulin secretion, reduced insulin sensitivity, and hyperglycemia. Diabetic wounds are among the major complications of T2DM and can lead to chronic wounds due to challenges in the normal healing process. In this study, a three-layered tissue scaffold incorporating microneedles (MNs) was developed for diabetic wound management. The scaffold was fabricated using digital light processing (DLP) for the GelMA-based layers and electrohydrodynamic atomization (EHDA) for the surface coating, combining antibacterial, metabolic, and antioxidant functions within a single platform. The first two layers were designed using gelatin methacrylate (GelMA) and produced via DLP. The first layer was loaded with the antibiotic amoxicillin to prevent infection at the scaffold application site. In the second layer, MNs containing metformin were designed. For the outermost layer, polylactic acid (PLA) microparticles containing antioxidant and antibacterial salicylic acid (SA) were produced via the EHDA method and coated onto the scaffold surface. This three-layered scaffold was characterized by SEM, FT-IR, DSC, and mechanical, swelling, degradation, and penetration analyses. In vitro studies of single-drug-loaded model formulations demonstrated biphasic drug-release behavior over 72 h, effective antibacterial activity against E. coli and S. aureus, and favorable cytocompatibility. Oxidative-stress assays showed lower Total Oxidant Status (TOS) levels and higher Total Antioxidant Status (TAS) values in the drug-loaded formulations, while the scratch assay demonstrated increased wound-gap closure under hyperglycemic culture conditions. Overall, the multilayer microneedle platform exhibited antibacterial activity, with inhibition zones of up to 23 mm, and favorable cytocompatibility, with cell viability remaining above 77% across all formulations. These findings provide in vitro proof-of-concept evidence for the multifunctional design of the platform but do not demonstrate wound-healing efficacy in diabetic tissue.
SN - 2470-1343
ER -